Article

Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease

Department of Radiology, University of California, San Diego, La Jolla, CA 92093-0841, USA.
Alzheimer disease and associated disorders (Impact Factor: 2.69). 07/2010; 24(3):269-77. DOI: 10.1097/WAD.0b013e3181d1b814
Source: PubMed

ABSTRACT We examined the improvement in statistical power that could be obtained in therapeutic trials for early (predementia) Alzheimer disease by constraining enrollment to individuals with amnestic mild cognitive impairment (MCI) and an atrophy pattern on a screening magnetic resonance imaging (MRI) scan previously found to be predictive of clinical decline, or to individuals with MCI and the apolipoprotein E epsilon 4 genetic risk factor for Alzheimer disease. Treatable effects were defined as absolute change versus change relative to healthy controls (HCs). Data from 168 HC and 299 MCI participants were analyzed to determine sample sizes required to detect 25% slowing in mean rate of decline using global function, cognitive function, and structural measures as outcome variables. Reductions in estimated sample sizes of 10% to 43% were observed using the genetic enrichment strategy; reductions of 43% to 60% were observed with the neuroimaging enrichment strategy. Sample sizes needed to detect slowing in rate of atrophy in MCI relative to HC were dramatically larger than those needed to detect absolute change in atrophy rates. Constraining enrollment to MCI subjects with predictive atrophy on a screening MRI scan could improve the efficiency of clinical trials. Failure to take into account normal age-related changes risks under-powering trials designed to test disease-modifying properties of potential treatments.

Download full-text

Full-text

Available from: Christine Fennema-Notestine, Jul 03, 2015
0 Followers
 · 
138 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Designers of clinical trials for Alzheimer's disease (AD) and mild cognitive impairment (MCI) are actively considering structural and functional neuroimaging, cerebrospinal fluid and genetic biomarkers to reduce the sample sizes needed to detect therapeutic effects. Genetic pre-selection, however, has been limited to Apolipoprotein E (ApoE). Recently discovered polymorphisms in the CLU, CR1 and PICALM genes are also moderate risk factors for AD; each affects lifetime AD risk by ~ 10-20%. Here, we tested the hypothesis that pre-selecting subjects based on these variants along with ApoE genotype would further boost clinical trial power, relative to considering ApoE alone, using an MRI-derived 2-year atrophy rate as our outcome measure. We ranked subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) based on their cumulative risk from these four genes. We obtained sample size estimates in cohorts enriched in subjects with greater aggregate genetic risk. Enriching for additional genetic biomarkers reduced the required sample sizes by up to 50%, for MCI trials. Thus, AD drug trial enrichment with multiple genotypes may have potential implications for the timeliness, cost, and power of trials.
    06/2013; 2. DOI:10.1016/j.nicl.2013.05.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article describes the successful VHDL design of a digital current control architecture for three phase electric drive systems, based on hardware implemented neural networks. The controller comprises an on-line inductance estimator and a PWM switching pattern generator based on a state space observer. Reconfigurable neural networks implemented with logic gates are involved in both. The complete development of the system has been achieved using VHDL and implemented into a single FPGA chip. The VHDL description of the neural networks has been automatically generated by C++ programs. The VHDL model of the motor controller allows the control over the hardware implementation complexity and therefore it can be readily adapted to the available hardware resources
    VHDL International Users Forum Fall Workshop, 2000. Proceedings; 02/2000
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vocoders compress speech by estimating model parameters at a given transmission rate over an analysis window, assuming that speech is stationary within this window. In this paper, the limits of this assumption are explored with regard to the spectral envelope parameters in the form of line spectral frequency (LSF) parameters. It is shown that all LSF parameters have considerable variations over time, regardless of LSF vector extraction and transmission rates. LSF track variations are investigated through oversampling and are shown to contain high frequency variations above the frequency corresponding to the LSF vector transmission rate. An anti-aliasing filter with cut-off frequency adequate for the chosen LSF vector transmission rate is proposed to alleviate possible spectral overlapping of the LSF parameter spectra. It is confirmed, through experiments, that the proposed method offers an advantage over the classic LSF extraction method with respect to quantisation shown by bit savings of typically 10 to 15%.
    Speech Coding, 2002, IEEE Workshop Proceedings.; 11/2002